PANCREATIC CANCER

This early-phase study tested the safety of a new cell therapy called huCART-meso cells in adults with advanced pancreatic cancer that could not be removed by surgery. The therapy involves collecting a patient's own immune cells (T-cells), modifying them in a lab to better target…

This study tested an experimental drug called VLS-101 (zilovertamab vedotin) in 102 people with advanced solid tumors that had spread and stopped responding to previous treatments. The trial aimed to see if the drug could shrink tumors and was safe for cancers including breast, l…

This early-stage study tested a new oral cancer drug called NUV-868, both alone and combined with existing medications (olaparib or enzalutamide), in adults with advanced solid tumors. The trial aimed to find safe doses and see if these treatments could help control cancers that …

This early-stage study tested a personalized cancer treatment that modifies a patient's own immune cells to recognize and attack their specific tumor mutations. The trial enrolled 8 adults with advanced solid tumors (including ovarian, lung, pancreatic, and colorectal cancers) wh…

This study tested whether the drug niraparib could help control advanced solid tumors in patients whose cancer has a specific genetic change called a PALB2 mutation. It involved 22 adults with various cancers (like breast, lung, or pancreatic) that had spread or were locally adva…

This early-stage study tested a new oral medication called IK-595 in adults with advanced solid tumors that have specific genetic changes (RAS or RAF mutations) and no remaining standard treatment options. The main goals were to find a safe dose, see how the body processes the dr…

This early-phase trial tested an experimental drug called SOT102 for people with advanced pancreatic cancer. Researchers wanted to see if SOT102 was safe and effective when given alone or alongside standard chemotherapy. The study was stopped early because concerning side effects…

This study tested a new drug called TAK-500, designed to activate the immune system to fight cancer. It was given alone or combined with an existing immunotherapy drug (pembrolizumab) to adults with advanced solid tumors that had stopped responding to standard treatments. The mai…

This study aimed to see if adding an experimental drug called BNT321 to standard chemotherapy (mFOLFIRINOX) could better prevent pancreatic cancer from returning after surgery. It was designed for patients who had their tumor completely removed. The sponsor stopped the trial earl…

This study tested whether adding a precise form of radiation therapy to standard chemotherapy could better control pain in people with advanced pancreatic cancer that has spread. Patients whose cancer was stable after initial chemo were randomly assigned to either continue chemo …

This study aimed to create a network and database to improve personalized treatment for people with advanced gastrointestinal cancers. It involved collecting and analyzing the genetic profiles of patients' tumors to see if they had specific mutations that could be targeted by exi…